5CV.F - CureVac N.V.

Frankfurt - Frankfurt 延遲價格。貨幣為 EUR。
8.56
+0.11 (+1.30%)
市場開市。 截至 12:44PM CEST。
你目前的瀏覽器並不支援股價圖表
前收市價8.45
開市8.38
買盤8.57 x 無
賣出價8.60 x 無
今日波幅8.38 - 8.56
52 週波幅5.30 - 17.65
成交量667
平均成交量10,108
市值1.916B
Beta 值 (5 年,每月)
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-1.42
業績公佈日
遠期股息及收益率無 (無)
除息日
1 年預測目標價72.97
  • Insider Monkey

    CureVac N.V. (NASDAQ:CVAC) Q4 2022 Earnings Call Transcript

    CureVac N.V. (NASDAQ:CVAC) Q4 2022 Earnings Call Transcript April 25, 2023 Operator: Greetings, and welcome to the CureVac Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. . As a reminder, this conference is being […]

  • Benzinga

    CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs

    CureVac N.V. (NASDAQ: CVAC) announced extended preliminary data from ongoing Phase 1 programs in COVID-19 and seasonal flu conducted in collaboration with GSK plc (NYSE: GSK). The newly reported data focus on older adult age groups. COVID-19 Program Newly reported immunogenicity data from CV0501 in older adults (age ≥65) are based on the fully recruited dose groups of 12, 25 and 50µg, consisting of 10 subjects per dose. On day 29 at the 12µg dose level, CV0501 generated a ratio of post-boost to

  • InvestorPlace

    7 Biotech Stocks That Will Make You Rich in 10 Years

    If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they’re seemingly one news item away from disaster. Further, the smaller enterprises in this exciting arena tend to be extremely unpredictable. Nevertheless, because the sector tends to run on its own fundamentals rather than abiding exclusively by traditional economic metrics, the biotech stocks that wil

  • Insider Monkey

    CureVac N.V. (NASDAQ:CVAC) Q3 2022 Earnings Call Transcript

    CureVac N.V. (NASDAQ:CVAC) Q3 2022 Earnings Call Transcript November 16, 2022 CureVac N.V. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.27. Operator: Greetings, and welcome to CureVac Third Quarter and First Nine Months 2022 Financial Results and Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session […]

  • Benzinga

    Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation

    CureVac N.V. (NASDAQ: CVAC) and GSK plc (NYSE: GSK) have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a booster dose to previous COVID-19 vaccination. The candidate, CV0501, is meant to be administered as a booster dose following the previous COVID-19 vaccination. GSK used CureVac's "second-generation mRNA backbone" to develop the vaccine. CureVac will test CV0501 in up to 180 healthy, COVID-19 vaccinated adults. The participants will receive a single

  • Benzinga

    BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac

    Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac N.V. (NASDAQ: CVAC). CureVac, earlier this month, filed a lawsuit in Germany against BioNTech over its use of mRNA technology. Related: CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech. It did not rule out further legal action against BioNTech's p

  • Insider Monkey

    10 Notable Market Movers to Watch on Wednesday

    In this article, we will take a look at the 10 notable market movers to watch on Wednesday. If you want to see some other stocks making big moves today, go directly to 5 Notable Market Movers to Watch on Wednesday. Pulp and paper company Resolute Forest Products Inc. (NYSE:RFP), electric vehicle maker Rivian Automotive, […]

  • Benzinga

    CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech

    CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development. CureVac has filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE (NASDAQ: BNTX) and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac’s intellectual property rights utilized in Comirnaty, BioNTech and Pfizer Inc’s (NYSE: PFE) mRN

  • Reuters

    CureVac files patent lawsuit in Germany against BioNTech over mRNA technology

    BERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus. The German-based biotech company is seeking "fair compensation" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday. When asked in a media call, Chief Executive Franz-Werner Haas did not rule out further legal action against BioNTech partner Pfizer or mRNA vaccine maker Moderna.